HELLS

Across TCGA pan-cancer cohorts, HELLS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HELLS data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher HELLS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated HELLS expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where HELLS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.920	0.498	<.001	39	view →
HNSC	DFS	Quartile	All	0.585	0.985	.026	21	view →
LUAD	DFS	Tertile	III,IV	0.972	0.384	.006	16	view →
GBM	DFS	Quartile	All	0.608	0.220	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HELLS–LSCC (DFS)

Open the LSCC breakdown →